Both ICE2LAST projects (2016 Phase 1 and 2018 Phase 2) center on ice-based stunning of aquatic animals using natural substances.
CUBI-PLAYA SL
Spanish SME that developed ice-based natural stunning technology to improve fish welfare and seafood quality at point of harvest.
Their core work
CUBI-PLAYA SL is a Spanish food-technology SME based in San Pedro del Pinatar, a coastal town in the Murcia region with a strong fishing and aquaculture tradition. The company developed ICE2LAST, a proprietary technology that integrates natural anesthetic substances directly into ice used during fish and seafood handling, stunning animals humanely prior to processing. This approach addresses both animal welfare standards in the fishing industry and — as a likely side effect — product quality improvements from reduced stress hormones in the catch. They progressed from concept validation to full commercial development entirely within the EU SME Instrument framework, acting as sole technical and commercial driver of the project.
What they specialise in
ICE2LAST Phase 1 explicitly references a 'natural anesthetizing agent in ice', indicating formulation expertise in food-safe bioactive compounds.
Both project descriptions list improved animal welfare as the central objective, positioning the company in regulatory compliance solutions for the fishing sector.
The company successfully navigated the full SME Instrument pathway (Phase 1 feasibility to Phase 2 market development), demonstrating capability in EU-funded product commercialization.
How they've shifted over time
CUBI-PLAYA's H2020 participation is entirely focused on a single innovation trajectory: the ICE2LAST technology. Between 2016 and 2020, they moved from a feasibility and concept-validation phase (SME Instrument Phase 1, €50,000) to a full development and market-entry phase (SME Instrument Phase 2, €682,246). There is no diversification visible — their commitment is deep and narrow, suggesting a company built around a single proprietary product rather than a broad research portfolio. The shift from early to recent phase reflects commercial maturation of one idea, not a change in research direction.
They are a single-product company that successfully scaled one technology through the full EU SME Instrument pipeline; future collaboration potential lies in deployment, licensing, or extension of ICE2LAST into adjacent seafood processing or aquaculture markets.
How they like to work
CUBI-PLAYA leads every project they join — both H2020 participations are as coordinator, with no partner roles. They work in very small or solo configurations, with only one unique consortium partner recorded across both projects. This pattern suggests a company that controls its own innovation agenda and is not accustomed to large multi-partner consortia; prospective partners should expect to join their agenda rather than co-define it.
Their recorded EU network is minimal — one unique partner in one country across two projects. This is consistent with the SME Instrument scheme, which is designed for single-company applicants and does not require large consortia.
What sets them apart
CUBI-PLAYA appears to be the originator of a specific niche technology — natural-substance ice stunning for fish — in a sector where animal welfare regulation is tightening across the EU. Their location in a major Spanish fishing region (Murcia coast) gives them direct industry proximity and likely real-world testing access that inland technology developers lack. For any consortium targeting food safety, sustainable fisheries, or aquaculture welfare compliance, they bring both the proprietary method and sector credibility.
Highlights from their portfolio
- ICE2LASTThe Phase 2 award of €682,246 under the SME Instrument is a competitive achievement, confirming EU evaluators judged the technology viable for market entry — a strong signal of commercial readiness.
- ICE2LASTThe full Phase 1 → Phase 2 progression under the same project name is rare and indicates a well-executed innovation trajectory from proof-of-concept to scale-up within four years.